01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
19:44 , Jun 5, 2019 |  BC Extra  |  Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
17:07 , May 11, 2018 |  BC Week In Review  |  Financial News

InflaRx raises $51M follow-on

Inflammatory diseases company InflaRx N.V. (NASDAQ:IFRX) raised $51 million on May 3 through the sale of 1.5 million shares at $34 in a follow-on underwritten by J.P. Morgan, Leerink, BMO Capital Markets and SunTrust Robinson...
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
21:23 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that IV IFX-1 (CaCP29) led to response rates of 75% at week 8...
20:43 , Nov 10, 2017 |  BC Week In Review  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Nov. 8 through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the...
19:12 , Nov 8, 2017 |  BC Extra  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Wednesday through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the midpoint...
21:14 , Oct 13, 2017 |  BC Week In Review  |  Financial News

InflaRx raises $55M in series D

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...